Investigational Drug Information for TRV130
✉ Email this page to a colleague
What is the drug development status for TRV130?
TRV130 is an investigational drug.
There have been 10 clinical trials for TRV130.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2016.
The most common disease conditions in clinical trials are Acute Pain, Fractures, Bone, and [disabled in preview]. The leading clinical trial sponsors are Trevena Inc., Lotus Clinical Research, LLC, and Kestrel Biologic.
There are sixteen US patents protecting this investigational drug and one hundred and eleven international patents.
Summary for TRV130
| US Patents | 16 |
| International Patents | 111 |
| US Patent Applications | 64 |
| WIPO Patent Applications | 41 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 3 (2016-05-01) |
| Vendors | 22 |
Recent Clinical Trials for TRV130
| Title | Sponsor | Phase |
|---|---|---|
| Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy | Trevena Inc. | Phase 3 |
| Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty | Trevena Inc. | Phase 3 |
| A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain | Trevena Inc. | Phase 3 |
Clinical Trial Summary for TRV130
Top disease conditions for TRV130
Top clinical trial sponsors for TRV130
US Patents for TRV130
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TRV130 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| TRV130 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| TRV130 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| TRV130 | See Plans and Pricing | Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery | MUCODEL PHARMA LLC (Greensboro, NC) | See Plans and Pricing |
| TRV130 | See Plans and Pricing | Methods of treating hyperalgesia | TREVENA, INC. (King of Prussia, PA) | See Plans and Pricing |
| TRV130 | See Plans and Pricing | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (King of Prussia, PA) | See Plans and Pricing |
| TRV130 | See Plans and Pricing | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (Philadelphia, PA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TRV130
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TRV130 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| TRV130 | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| TRV130 | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| TRV130 | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| TRV130 | Hong Kong | HK1249728 | 2036-05-05 | See Plans and Pricing |
| TRV130 | Japan | JP2019520866 | 2036-05-05 | See Plans and Pricing |
| TRV130 | Japan | JP6559912 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
